Myovant Sciences Ltd. (MYOV) expects to raise $176 million in an initial public offering on Thursday, October 27th. The company will issue 13,000,000 shares at $12.00-$15.00 per share.

The company has a market-cap of $790 million.

Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Myovant Sciences Ltd. provided the following description of their company for its IPO: “We are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health diseases and other endocrine-related disorders. Our lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone, or GnRH, receptor antagonist. We are advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and advanced prostate cancer. “.

Myovant Sciences Ltd. was founded in 2016 and has 9 employees. The company is located at Clarendon House 2 Church Street, Hamilton HM 11, Bermuda and can be reached via phone at +1 (441) 824-8101.

Receive News & Ratings for Myovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd. and related companies with's FREE daily email newsletter.